Protein / target
Tumor necrosis factor receptor superfamily member 17
Protein at a glance
Biological role
Signaling receptor activity
Strongest disease association
gastric carcinoma
Therapeutic maturity
Clinically validated target
Druggability
Antibody
Clinical development
5 approved
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function
Receptor for TNFSF13B/BLyS/BAFF and TNFSF13/APRIL. Promotes B-cell survival and plays a role in the regulation of humoral immunity. Activates NF-kappa-B and JNK
Subcellular location
Domains and Gene Ontology detail (7)Hide
Gene Ontology
- Cendomembrane system
- Cmembrane
- Cplasma membrane
- Fsignaling receptor activity
- Padaptive immune response
- Psignal transduction
- Ptumor necrosis factor-mediated signaling pathway
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Immune signalling
- ·adaptive immune response
View underlying pathways (1)Hide underlying pathways
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Interaction neighbourhood
Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.
Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.
Drugs targeting this protein
Whether each drug engages this protein directly or through a complex, and how many other targets are recorded for it. Direct binders with few recorded targets are listed first.
Tumor necrosis factor receptor superfamily member 17 binding agent
Appears in clinical studies involving plasma cell myeloma, vascular hemostatic disease, immunoproliferative disorder, hemorrhagic disease
Tumor necrosis factor receptor superfamily member 17 binding agent
Appears in clinical studies involving plasma cell myeloma, neoplasm, hematopoietic and lymphoid cell neoplasm, smoldering plasma cell myeloma
ChEMBL mechanism, action type and target identity. Open Targets clinical status and indications.
Translational evidence
Why this target matters therapeutically — disease associations, drugs in development, tractability and safety, from Open Targets.
Strongest genetic associations
Human genetic evidence — the most direct causal link between this target and a disease.
Highest-confidence therapeutic associations
Diseases where a drug acting on this target has already reached clinical development.
Highest overall evidence
Remaining associations by Open Targets' aggregated evidence score.
Show all associationsHide all associations
Open Targets ranks 436 associations for this target and we store the top 10 by aggregated score. The long tail is largely literature co-mention and RNA-expression evidence, not evidence that this target drives those diseases.
Known drugs · 5 total
plasma cell myeloma · vascular hemostatic disease · immunoproliferative disorder
plasma cell myeloma · neoplasm · hematopoietic and lymphoid cell neoplasm
plasma cell myeloma · plasma cell myeloma · smoldering plasma cell myeloma
plasma cell myeloma · neoplasm · smoldering plasma cell myeloma
plasma cell myeloma · neoplasm · plasma cell myeloma
Tractability
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein.
Show remaining trials (24)Hide
ClinicalTrials.gov via the drug-target graph.
Forefront confidence
Our own weighting of the evidence behind each disease association. Human genetics and clinical evidence count for most; literature co-mention counts for little, because two entities sharing an abstract is not evidence that one drives the other.
The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the underlying per-type scores are shown above so the calculation can be checked.
What's happening now
Recent activity around this target, drawn from one canonical event stream. Every item is reached through 2 drugs that target this protein, so each event is news about that drug rather than about the protein directly.
- Regulatory approval
Approval: Blenrep (EMA)
- Withdrawn from market
Market withdrawal: Blenrep (EMA)
- Regulatory approval
Approval: Abecma (EMA)
- New publicationIdecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
- New publicationBCMA-targeted immunotherapy for multiple myeloma.
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.